Shasta E. Henderson

Shasta E. Henderson

Auto-generated profile, based on publicly available information

Shasta E. Henderson

Department of Orthopaedics, Pennsylvania State University, Hershey, Pennsylvania

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
SHShasta Henderson
Shasta Henderson
IIIzuchukwu Ibe
Izuchukwu Ibe
SCSean Cahill
Sean Cahill
Yeon Ho ChungYeon Ho Chung
Yeon Ho Chung
FLFrancis Y Lee
Francis Y Lee
➤ Patients with type-1 or type-2 diabetes have an increased risk of fracture, which is secondary to early bone loss in type-1 diabetes whereas, in type 2, the development of abnormal osseous architecture results in paradoxically increased or normal bone mineral density. ➤ Diabetic patients diagnosed with osteoporosis should receive the same standard antiresorptive therapies as non-diabetic patients in conjunction with appropriate glycemic control. ➤ Medical management of type-2 diabetes can affect bone health and fracture risk. Thiazolidinediones have been correlated with an increased facture risk, whereas metformin can be protective of the bone health of diabetic patients. ➤ Diabetes increases the likelihood of nonunion and delayed union of fractures as well as other perioperative complications such as infection. ➤ Perioperative glycemic control may decrease the risk of perioperative complications, especially surgical site infection. Methods to directly improve diabetic fracture-healing such as the use of parathyroid hormone and sclerostin antibody are in the experimental phase. ➤ Prior to proceeding with operative intervention for fractures, it is necessary to consider the additional risk posed by diabetes, which must be taken into account when planning the approach, fixation, and postoperative management in this population.

1 July 2019 in JBJS Essential Surgical Techniques
Verified
Journal Article
Closed access
IIIzuchukwu K. Ibe
Izuchukwu K. Ibe
KAKareme D. Alder
Kareme D. Alder
SHShasta E. Henderson
Shasta E. Henderson
KYKristin E. Yu
Kristin E. Yu
FLFrancis Y Lee
Francis Y Lee
Background: There are many treatment modalities for benign cystic lesions of bone, but all methods, except for total resection, are plagued with varying rates of recurrence 1 . Thorough curettage with the use of a high-speed burr, however, has demonstrated a low recurrence rate of 12% and has been suggested to be the best method for the treatment of benign cystic lesions. Approximately 90% of aneurysmal bone cysts can be controlled adequately with this treatment alone 2 . Description: Treatment of benign cystic lesions of bone with the use of excisional curettage requires careful preoperative planning and patient positioning before the initial incision is made. The initial incision must be carefully planned to expose the entire lesion without violating multiple compartments unnecessarily. A sizeable cortical window must then be made using a high-speed burr followed by evacuation of all cystic contents via curettage. The cavity is copiously irrigated before an adjuvant is used, and the lesion is stabilized, if necessary, before closing. Alternatives: There are many types of alternatives to curettage, such as wide resection, radiation, and embolization of feeding vessels. Rationale: In orthopaedics, as in all medical specialties, many interventions and techniques have been rendered obsolete and, ultimately, replaced by newer, safer, and more efficient ones. The appeal of curettage has remained because of its procedural simplicity and adaptability in the management of a plethora of diseases such as benign cystic lesions of bone. Additionally, curettage, unlike wide resection, radiation, and embolization of feeding vessels, is minimally invasive and often definitive in nature when used as a treatment modality 2 . Lastly, curettage grants the performing surgeon the ability to maintain a contained cavity that can be treated with a variety of adjuvant therapies 3–17 . These reasons listed above make curettage a viable option for the surgical treatment of benign cystic lesions such as giant cell tumors of bone, aneurysmal bone cysts, unicameral bone cysts, chondromyxoid fibromas, and symptomatic nonossifying fibromas.